Regeneron To Receive 42.75 Million From Novartis To Satisfy Novartis' Remaining Funding Obligation For Development Of The IL-1 T
Regeneron Also Achieves Development Milestone, Resulting In Loan Forgiveness
The companies agreed that their collaboration with respect to the IL-1 Trap would end on April 15, 2004 and all rights to the IL-1 Trap will then revert to Regeneron. Regeneron and Novartis each retain rights under their agreement to elect to collaborate in the future on the development and commercialization of certain other IL-1 antagonists.
Regeneron plans to initiate a Phase IIb study of the IL-1 Trap in patients with rheumatoid arthritis later in 2004. It also intends to conduct studies of the IL-1 Trap in a variety of other inflammatory diseases where interleukin-1 is believed to play a critical role.
Most read news
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.